Vantis Vascular, Inc.

Vantis Vascular, Inc. is a physician-founded medical device company specializing in innovative vascular intervention technologies for interventional cardiologists and vascular interventionalists. The company develops advanced delivery systems and tools designed to improve procedural outcomes in complex coronary and peripheral vascular interventions. CrossFast™ is their primary commercial product—an advanced vascular delivery system featuring a two-as-one design combining an auto-locking inner monorail microcatheter and outer delivery catheter engineered for precise control during percutaneous coronary intervention (PCI) procedures in complex, calcified, and tortuous anatomies. The system is designed to enhance deliverability, increase intubation depth, and minimize tissue trauma through seamless transitions and an atraumatic tip design. Vantis is also developing next-generation intravascular lithotripsy (IVL) technology in conjunction with CrossFast to treat complex calcified lesions, and specialized peripheral below-the-knee (BTK) vascular delivery solutions. The company is led by experienced medtech executives and clinician-scientists with deep expertise in cardiovascular device development, regulatory affairs, and commercialization. The management team collectively brings over 200 years of combined experience across multiple successful medical device ventures, many of which have been acquired by major industry players. Vantis maintains robust regulatory and quality capabilities with leadership experienced in FDA, EMA, and global regulatory compliance. The company is based in San Jose, California, and targets interventional cardiology labs, cath labs, and peripheral vascular intervention centers.